AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
52 hedge funds and large institutions have $92.7M invested in AVEO Pharmaceuticals, Inc. in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 14 reducing their positions, and 23 closing their positions.
45% more call options, than puts
Call options by funds: $3.37M | Put options by funds: $2.32M
0% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 14
1% less capital invested
Capital invested by funds: $94M → $92.7M (-$1.29M)
17% less funds holding
Funds holding: 63 → 52 (-11)
48% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$11.9M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$2.72M |
| 3 |
Millennium Management
New York
|
+$1.32M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$940K |
| 5 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$775K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.89M |
| 2 |
Renaissance Technologies
New York
|
-$1.48M |
| 3 |
Two Sigma Investments
New York
|
-$1.4M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$1.27M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.14M |
AVEO Hedge Fund Activity: Q3 2021 in Review
52 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2021, worth a combined $92.7M — down 1.4% from $94M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of AVEO and 12 opened new positions — a net loss of 11 holders — while 14 trimmed existing stakes and 14 added.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $11.9M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $5.89M sold.
- 52 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2021, down from 63 in Q2 2021.
- Funds reported $92.7M of AVEO Pharmaceuticals, Inc. stock for Q3 2021, down 1.4% quarter-over-quarter.
- 12 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2021 and 23 closed out, a net change of -11 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2021 was AIGH Capital Management, an estimated $11.9M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q3 2021 was Cormorant Asset Management, an estimated $5.89M sold.
Based on aggregated 13F filings for Q3 2021.